Property Summary

NCBI Gene PubMed Count 259
PubMed Score 533.46
PubTator Score 531.88

Knowledge Summary

Patent

No data available

Protein-protein Interaction (9)

Gene RIF (282)

PMID Text
27455553 The HEK-293 cell lines stably expressing human OATP1B1-wild and variant (HEK-OATP1B1, *1b and *15) are potential models to study drug transport in vitro
26607661 SLCO1B1 variants are strongly associated with an increased risk of enalapril-induced cough.
26562723 TM11 of OATP1B1 may face the substrate interaction pocket.
26482301 The SLCO1B1 rs1104581 polymorphism, weight, and gender appear to play important roles for rifabutin efficiency in African HIV-Infected patients with tuberculosis.
26474710 OATP1B1- and OATP1B3-humanized mice can be used as in vivo tools to assess and possibly predict clinically relevant DDIs.
26409184 Results identified interethnic differences of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes in Korean population compared with other ethnic groups.
26383540 transport of CPR I mediated by OATP1B1 and OATP1B3 and the transport of CPR III mediated by OATPs 1B1, 1B3 and 2B1 is time-dependent, can be saturated and inhibited
26380303 Patients with better muscle function had the highest concentration of CK, IL-1, and TNF-a compared with less muscle function
26376374 T521C polymorphism associated with an increased risk of statin-related myopathy, especially in individuals receiving simvastatin [review]
26373210 this extensive analysis of the effect of SLCO1B1 polymorphisms on the pharmacokinetic profile of atorvastatin showed that SNPs may affect the inter-individual response to atorvastatin
26334733 these results suggest that the pharmacogenetical pattern of SLCO1B1 gene shows population specificity; therefore the examination of clinically relevant polymorphisms is important in different populations.
26334272 the polymorphism rs2306283 at the SLCO1B1 gene determines greater HDL-C concentrations in response to atorvastatin medication in Chilean hypercholesterolemic subjects.
26191226 Down-regulation of OATP1B1/3 proteins may contribute to pathogenesis of jaundice accompanying advanced cholestatic liver diseases.
26146841 SLCO1B1 and SLCO1B3 polymorphisms contributed to an increased risk of neonatal hyperbilirubinemia.
26122863 Misoprostol acid was transported across a blood-brain barrier model by MRP4 and SLCO1B1
26009271 Taken together, our present study demonstrated that PKC regulates the function of OATP1B1 by affecting internalization and recycling of the transporter protein.
25992810 In Czech dyslipidemia patients treated with low simvastatin or atorvastatin doses, there is no association between SLCO1B1 rs4363657 polymorphism and risk of myalgia/myopathy.
25935875 Results show ticagrelor pharmacokinetics to be influenced by SNPs in SLCO1B1 though no detectable effects on efficacy or safety were found
25916517 Functional SLCO1B1 variants are not associated with death/myocardial infarction in patients commonly treated with statins.
25812934 The mutations of OATP1B1 388GG and 521CC inhibited the activity of OATP1B1 protein, restrained the turnover capacity of OATP1B1 and reduced the entrance of tamoxifen into MCF-7 cells, resulting in weakened efficacy in the treatment of breast cancer.
25701109 The aim of this study was to evaluate the association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms with overall survival for breast cancer patients after adjuvant tamoxifen therapy.
25578040 Data suggest that expression of SLCO1B1 and SLCO1B3 in hepatocytes can be regulated by dietary factors; expression of SLCO1B1 is up-regulated by anthocyanins/anthocyanin glycosides; expression of SLCO1B3 is down-regulated by these fruit pigments.
25499601 Genetic variation in SLCO1b1 may be associated with change in mammographic density after women stop using estrogen-progestin therapy.
25498879 Results show that patients carrying at least one SLCO1b1 haplotype have increased risk of ATDH
25488931 Data (including data from cloned cells expressing various levels of recombinant proteins) verify that level of expression of OATP1B1 or BCRP in plasma membrane correlates with transport of drugs (transport of estradiol glucuronide by OATP1B1).
25414411 Data suggest that competitive inhibition of biological transport via OATP1B1 may account for drug-drug interactions; specificity of OATP1B1 in transport of various drugs may be key factor leading to drug-drug interactions.
25391605 UGT1A1, SLCO1B1 and SLCO1B3 polymorphisms become risk factors in neonates showing 10% or greater body weight loss during the neonatal period. Inadequate feeding may increase the bilirubin burden and cause apparent hyperbilirubinemia in neonates.
25379722 Genetic variants of OATP1B1 leading to impaired hepatic uptake of statins translated into reduced drug efficacy in a population-based cohort.
25130190 SLCO1B1 c.521T > C variant decreases the clearance of methotrexate in childhood acute lymphoblastic leukemia.
25124723 SLCO1B1 genotype may help to identify patients with increased risk of methotrexate-related toxicity.
25098908 Results shown that SLCO1B1 polymorphisms influence methotrexate disposition and survival in methotrexate-treated osteosarcoma patients and therefore might serve as pharmacogenetic markers of treatment outcome.
25084202 There was no association between the plasma LDL-C levels and the expression and activity of ABCB1 and OATP1B1
24989890 A pronounced OATP1B1 and comparatively low OATP1B3 protein expression in the investigated hepatocyte lot.
24865931 study demonstrates that UGT1A1 and OATP2 polymorphisms were associated with altered bilirubin metabolism and could be genetic risk factors for neonatal hyperbilirubinemia
24855184 The expression of OATP1B1 and -1B3 in the humanized models did not significantly alter liver or plasma concentrations of rosuvastatin.
24825069 human OATP1B1, OATP1B3 and OATP1A2 can transport docetaxel in vivo.
24810685 The review shows that among all the loci identified, only the *5 allele of SLCO1B1 was strongly and consistently associated with the onset of myopathy.
24762081 Our results, for the first time, indicated that polymorphisms of SLCO1B1 rs2306283 might be associated with bladder cancer risk.
24740327 Data indicate that HEK-293T cells expressing liver specific organic anion transporter peptides OATP1B1 and OATP1B3 undergo apoptosis upon nodularin treatment.
24673529 results strongly suggest that SLOL1B1 is part of the estrone-3-sulfate binding site/translocation pathway but is not directly involved in binding/translocation of estradiol-17beta-glucuronide
24623479 This study investigates the effect of OATP1B1 genotype as a covariate on repaglinide pharmacokinetics and drug-drug interaction risk using a reduced physiologically-based pharmacokinetic model.
24595600 Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
24420746 Male sex and SLCO1B1c.463CA genotype increase the risk of lower rifampin plasma exposure.
24263182 In the Rotterdam Study, results show an association between c.521T>C polymorphism of SLCO1B1 and dose decrease or switching, as indicators of adverse drug reactions, and provided risk factors for this association.
24194513 Knockin of OATP1B1 or OATP1B3 partially restored control clearance.
24090270 SLCO1B1 polymorphic variant is asscociated with neonatal hyperbilirubinemia in Chinese neonates.
23970802 Common variants in SLCO1B1 were associated with differences in arsenic metabolites in a preliminary candidate gene study.
23942138 data replicate the association of SLCO1B1 variants with statin-induced myopathy.
23930675 Polymorphisms in CYP2C9, CYP2C19 and SLC10A1 had minimal lipid-lowering effects.
23929842 B cell deficiency attenuates Oatp1a4 mRNA expression in immune-mediated liver disease.
23886114 In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
23858103 Trp258 and Trp259 play different roles in the uptake of different substrates by OATP1B1.
23850112 This study demonstrated that the 388 G>A mutation of the SLCO1B1 gene is a risk factor for developing neonatal hyperbilirubinemia in Chinese neonates, but not in white, Thai, Brazilian, or Malaysian populations
23778707 polymorphisms for which there is a compelling body of literature supporting their clinical relevance: OATP1B1 (c.521T>C, p.V174A, rs4149056) .... The clinical evidence demonstrating their role in variation in pharmacokinetics and pharmacodynamics
23708174 There appears to be no increased risk of myalgia among users of rosuvastatin who carry the rs4363657C or the rs4149056C allele in SLCO1B1.
23670789 Treatment with SD rifampin, which inhibits the OATP1B1/3 transporter system, did not substantially influence the SD pharmacokinetics of anacetrapib.
23652803 SLCO1B1 rs4149056 variant is associated with stomatitis in childhood acute lymphoblastic leukemia.
23625433 There was no significant difference in pharmacokinetic parameters or hypoglycemic effects of repaglinide among SLCO1B1 genotypes in either the pitavastatin or control group.
23556337 Compared to non-SLCO1B1*17 carriers, SLCO1B1*17 carriers had higher peak plasma concentration and AUC of the acid and lactone forms of pivastatin
23503447 SLCO1B1 521T-C tends to be associated with higher lopinavir concentrations in AIDS patients with targeted polymorphisms.
23471819 Report PCR method for direct/rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens.
23461378 a role of OATP1B1 in the hepatic uptake of xenobiotics into human hepatocytes
23436703 This review discusses gene-drug interactions, including a proposed dynamic effect on statin therapy by genetic variants in SLCO1B1 and CYP3A4 in liver cells, the main target site where statins block cholesterol synthesis. [review]
23361102 OATP1B1 phenotype is more important than CYP3A4 and MDR1 phenotypes for the individual pharmacokinetic variability of atorvastatin.
23340295 These findings signify a unique role for OATP1B1 and OATP1B3 in the elimination of sorafenib-glucuronide and suggest a role for these transporters in the in vivo handling of glucuronic acid conjugates of drugs.
23285087 Asparagine residues that are possibly involved in N-glycosylation were substituted with glutamine residues and identified three glycosylation sites (Asn134, Asn503 and Asn516) within the structure of OATP1B1.
23263738 SLCO1B1 polymorphisms were not associated with the lipid-lowering effects of atorvastatin and simvastatin in Chinese hyperlipidemics.
23248200 Several oral antidiabetic drugs affect the OATP1B1-mediated uptake of rosuvastatin in vitro.
23243220 Human OATP1A/1B transporters play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutics methotrexate ( and paclitaxel
23233662 Data show that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 SNP rs4149056.
23216274 study aims to investigate the relationship between colorectal cancer and the functional common variants of SLCO1B1 (OATP1B1) and to estimate the prevalence of these variants in the Turkish population
23190519 in end-stage renal failure patients, some uremic toxins are related to the downregulation of intestinal MRP2 and hepatic OATP1B1 and/or OATP2B1.
23010650 review discusses the potential influence of extrahepatic OATP1B expression on homeostasis and pathophysiology and its implications for pharmacotherapy in general [review]
22842957 Both SLCO1B1 521 T>C and the CYP2C9*3 polymorphisms can significantly affect the pharmacokinetics of nateglinide.
22771883 Genetic polymorphisms of OATP1B1 are signal confounders in gadoxetic acid-enhanced liver MR imaging. No pharmacokinetic characteristics of gadoxetic acid were influenced by genetic polymorphisms of OATP1B1 and OATP1B3.
22749334 Polymorphisms in SLCO1B1 were not associated with serum bilirubin levels in Chinese patients. Statins increased bilirubin levels and this effect was independent of the polymorphisms.
22695893 there was no remarkable difference in any pharmacokinetic parameters of olmesartan between subjects with and without any major haplotypes in the three transporter genes we tested- SLCO1B1, SLCO1B3 and ABCC2
22574206 amino acids essential for estrone-3-sulfate transport function of OATP1B1
22562052 the OATP1B1 *15 haplotype is an important predisposing factor for rifampin-induced liver injury.
22505549 SLCO1B1 c.388A>G polymorphism could play a role in the inter-individual variation of clinical response to simvastatin in Brazilians
22240838 Cyclosporine A has a long-lasting inhibitory effect on OATP1B1 and OATP1B3.
22232210 Data show that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3.
22203093 OATP1B1 mRNA was detected in intrahepatic cholestasis of pregnancy placentas and control placentas, but protein expression of OATP1B1 was not found in any of the placentas.
22189199 Presence of the rs4149056 non-synonymous SNP at the SLCO1B1 gene locus can significantly decrease the pravastatin induced LDL cholesterol lowering response in the elderly.
22178260 We found that the frequencies of polymorphisms and haplotypes of ABCB1, SLCO1B1 and ABCC2 were similar in patients with ATD-induced hepatitis and ATD-tolerant controls.
22147369 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
22136368 genotype and haplotype distributions are highly variable among populations of the same self-reported colour and geographical region
22088425 The SLCO1B1 *1b haplotype was significantly associated with peptic ulcer.
22041697 is expressed on the basolateral membrane of hepatocytes and can facilitate hepatic uptake of certain clinically relevant drugs.(review)
22016628 Data indicate that organic anion transporter SLCO1B1 c.388A>G polymorphism causes significant increase in atorvastatin response and may be a marker for predicting efficacy of lipid-lowering therapy.
21992719 SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.
21902813 gender, but not SLCO1B1 or CYP7A1 polymorphism, has a major effect on the fasting plasma concentrations of individual bile acids
21882531 Subjects with the 521T --> C mutation in OATP1B1 absorbed less rosuvastatin than subjects without the mutation.
21851379 The rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin.
21849517 Digoxin inhibited the uptake of probe substrates of OATP1B1 (IC(50) of 47 muM), OATP1B3 (IC(50) > 8.1 muM), and OATP2B1 (IC(50) > 300 muM), but not OATP1A2 in transfected cell lines.
21787759 This study demonstrated that plated primary human hepatocytes are useful as an in vitro model for OATP1B1/1B3-mediated uptake studies, but the culture time may substantially change the uptake kinetics.
21743379 There was no statistically significant association between LPV or RTV AUC or CL, and CYP3A5, ABCB1, or SLCO1B1 A388G polymorphisms.
21719246 Data suggest OATP1B1 and OATP1B3 are high-affinity paclitaxel transporters expressed in ovarian cancer cell lines and tumor tissues (or when expressed as recombinant proteins in Xenopus laevis oocytes).
21709081 SLCO1B1 rs4149032 was present in most patients and was associated with substantially reduced rifampin exposure
21691816 we studied a series of hepatocellular carcinomas from livers that underwent liver transplantation and correlated the expression of OATP 1B1/1B3 with morphological features
21655991 Genetic polymorphism in SLCO1B1 does not affect pharmacokinetics of UDCA, suggesting that OATP1B1 is not rate-limiting to the hepatic uptake of therapeutic UDCA.
21500146 Male sex and two polymorphic forms of the OATP-2 gene (388/411-411 and 388-411) increased the risk of neonatal nonphysiological hyperbilirubinemia.
21457551 study found evidence that genetic variation in SLCO1B1 is associated with breast cancer risk in postmenopausal women, particularly among those using estrogen-progestin therapy
21327909 SLCO1B1*1B/*1B genotype is associated with reduced pharmacokinetic exposure after a single dose oral administration of 2 mg repaglinide, including decreased AUC(0-infinity) and increased clearance of repaglinide.
21309757 findings show one SNP (i.e., rs4149014) showed correlation with essential hypertension (EH) in the Uyghur population; the minor allele of SNP rs4149014 at the SLCO1B1 promoter showed association with increased risk for EH
21245207 OATP1B1, current knowledge: expression, function, substrate characteristics, pharmacogenetics, and role in drug interactions [REVIEW]
21243006 Findings provide further support for a role for SLCO1B1 genotype in simvastatin-associated myopathy, and suggest that this association may be stronger for simvastatin compared with atorvastatin.
21092521 OATP1B1 A388G polymorphism has a notable influence on the serum bilirubin level in neonatal hyperbilirubinemia patients.
21072184 Results indicated both flavopiridol and flavopiridol-glucuronide are substrates of the SLCO1B1/OATP1B1 transporter.
21072184 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20973885 Observational study of gene-disease association. (HuGE Navigator)
20877131 Forty nine nucleotide sequence variants leading to ten major haplotypes in the SLCO1B1 gene were identified in caucasian Canadians.
20877131 Observational study of genotype prevalence. (HuGE Navigator)
20839930 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20837016 Observational study of gene-disease association. (HuGE Navigator)
20827719 OATP1B1 and nuclear receptors may play an important and heretofore unrecognized role during cholestasis nd drug-induced liver injury.
20712525 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20679960 Observational study of gene-disease association. (HuGE Navigator)
20660695 Polymorphisms in the SLCO1B1 gene associated with lower rifampin exposure were more frequent among black subjects.
20660695 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20635135 data suggest that among the many known transporters common variations of PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 do not contribute to breast carcinogenesis
20635135 Observational study of gene-disease association. (HuGE Navigator)
20602615 Observational study of gene-disease association. (HuGE Navigator)
20514852 Variants of OATP2 gene were not significant risk factors associated with severe hyperbilirubinemia in Malaysian Chinese infants.
20514852 Observational study of gene-disease association. (HuGE Navigator)
20406215 SLCO1B1 polymorphism unlikely affects the response to these antidiabetics.
20403997 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20389299 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20347093 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20212519 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20207952 Clinical trial of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20175818 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20173083 Observational study of genotype prevalence. (HuGE Navigator)
20078617 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20051929 Antiretroviral protease inhibitors, but not non-nucleoside reverse transcriptase inhibitors, are substrates for OATP1A2, OATP1B1 and OATP1B3.
20040338 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
20031551 Observational study of gene-disease association. (HuGE Navigator)
19956635 Uncategorized study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19952871 SLCO1B1 is a very important pharmacogene.
19934028 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19901119 Germline genetic variation in SLCO1B1 is associated with methotrexate pharmacokinetics and clinical effects.
19901119 Observational study and genome-wide association study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19890249 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19858149 coexpression of the G6PD African A- mutation with UGT1A1 and/or SLCO1B1 variants was seen more frequently in neonatal hyperbilirubinemia
19858149 Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
19842932 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19833260 SLCO1B1*5 genotype and female sex were associated mild statin-induced myalgia side effects.
19833260 Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19776292 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19771428 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19760661 Functional studies of chimeras showed that transmembrane domain 10 is critical for the function of OATP1B1.
19667110 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19642078 Observational study of gene-disease association. (HuGE Navigator)
19620935 Observational study of gene-disease association. (HuGE Navigator)
19590950 We analysed 48,000 gene transcripts in 132 invasive breast carcinomas to identify two novel genes (OATP2 and FABP7) significantly associated with the basal-like or basal phenotype class of breast cancers
19442037 In this review, organic anion transporting polypeptide (OATP)1B1 is an uptake transporter specifically expressed in the liver, and is considered important for drugs, particularly as its pharmacological target organ is the liver.
19414484 Genetic variation of UGT1A1 and SLCO1B1 is associated with the total serum bilirubin levels.
19414484 Meta-analysis and genome-wide association study of gene-disease association. (HuGE Navigator)
19397531 Thai infants with variant in the UGT1A1 at nt 211 or with G-6-PD deficiency are at higher risk for developing neonatal hyperbilirubinemia.
19397531 Observational study of gene-disease association. (HuGE Navigator)
19390945 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19387419 SLCO1B1 polymorphism considerably affects the disposition of several endogenous bile acids and bile acid synthesis marker.indicating that OATP1B1 plays an important role in the hepatic uptake of bile acids in vivo in humans
19387419 Observational study of gene-disease association. (HuGE Navigator)
19374892 Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19349540 Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19343046 Observational study of gene-disease association. (HuGE Navigator)
19293444 The SLCO1B1 gene 388A>G polymorphism does not appear to play a significant role in susceptibility to gallstone formation.
19293444 Observational study of gene-disease association. (HuGE Navigator)
19243019 Observational study of gene-disease association. (HuGE Navigator)
19238654 The extent of gemfibrozil-repaglinide interaction depends on SLCO1B1 genotype.
19238654 Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19238116 Observational study of gene-disease association. (HuGE Navigator)
19129086 Polymorphisms in the CYP2C8 drug-metabolising enzyme gene, but not the SLCO1B1 drug transporter gene, significantly influence rosiglitazone disposition in humans.
19129086 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
19122343 Genetic variations of SLCO1B1 are identified in the three major ethnic groups (Chinese, Malay, and Indian) of the Singaporean population in this first comprehensive analysis of the SLCO1B1 gene in an Asian population.
19122343 Observational study of genotype prevalence. (HuGE Navigator)
19005461 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18854776 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18823304 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18794729 low activity SLCO1B1 c.521CC genotype is associated with an increased cholesterol synthesis rat
18794729 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18781850 The common *14 allele of OATP1B1, which is distinguished by the presence of the c.463C>A polymorphism, is associated with enhanced lipid-lowering efficacy in this study.
18781850 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18695635 SLCO1B1 polymorphism significantly influences plasma mycophenolic acid glucuronide pharmacokinetics in Japanese renal transplant recipients.
18650507 We have identified common variants in SLCO1B1 that are strongly associated with an increased risk of statin-induced myopathy.
18641915 SLCO1B1 polymorphism is associated with Pharmacokinetic interaction between pravastatin and olmesartan.
18558634 Eight nonsynonymous OATP1B1 gene variants were detected in children with hereditary hyperbilirubinemia; degree of genetic heterogeneity and variant coexpression across OATP1B1 gene points to polygenic nature of this disease.
18558634 Observational study of genotype prevalence. (HuGE Navigator)
18551036 Pharmacokinetics of ezetimibe is influenced by OATP1B1 polymorphisms in healthy participants after single dose administration.
18551036 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18518855 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18499754 OATP1B1-Ala174 displays decreased transport activity and thereby gives rise to higher bilirubin, estrone sulfate, and T4 sulfate levels in carriers of this polymorphism.
18499754 Observational study of gene-disease association. (HuGE Navigator)
18443034 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18408565 Substrate dependency in the consequences of the SLCO1B1*15 variant could modulate the effect of SLCO1B1 polymorphism on the disposition of pitavastatin and pravastatin.
18408565 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18399713 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18321482 Pregnane X receptor ligands, by inhibiting OATP1B1-mediated uptake, can lead to drug-drug interactions at the transporter level.
18314419 Alterations of OATP1BB1 function by oral antidiabetic drugs have to be considered as potential mechanisms underlying drug-drug interactions.
18221820 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18192894 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
18187595 SLCO1B1 polymorphism had no significant effect on the plasma pharmacokinetics or pharmacodynamics of nateglinide or its M7 metabolite.
18187595 Observational study of gene-disease association. (HuGE Navigator)
18185926 results demonstrate a high sequence variability of OATP1B1 within different popuations
18185926 Observational study of genotype prevalence. (HuGE Navigator)
18180273 A set of double transfectants expressing OATP1B3 combined with OAT1B1 can be used as a tool for rapid identification of hepatic uptake and efflux transporters of many organic anions that are substrates of OATP1B1 or OATP1B3.
18159134 Observational study of genotype prevalence. (HuGE Navigator)
18159134 Indicated genetic variation in SLCO1B1 in Japanese population.
18154446 selective pressure may have acted on SLCO1B1 during human dispersal favoring low-activity variants in the north
18154446 Observational study of genotype prevalence. (HuGE Navigator)
17996736 most common allele was SLCO1B1*1b, while SLCO1B1*5 was rare or abse
17996736 Observational study of genotype prevalence and genetic testing. (HuGE Navigator)
17989996 Data demonstrated that the frequent SLCO1B1 SNP c.1929A>C had no effect on the hepatic OATP1B1 protein expression and on the transport properties.
17989996 Observational study of genotype prevalence. (HuGE Navigator)
17973861 Observational study of gene-disease association. (HuGE Navigator)
17973861 Genetic polymorphism in SLCO1B1 is a major determinant of interindividual variability in the serum bilirubin level.
17932728 HNF1alpha is an essential regulator of OATP1B1 mRNA expression and thus the level of HNF1alpha expression is one of the major determinants of interindividual variability in OATP1B1 mRNA expression.
17923851 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17906856 Observational study of gene-disease association, gene-gene interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17885626 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17883959 Observational study of genotype prevalence. (HuGE Navigator)
17766002 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17641954 cAMP-PKA regulation of OATPC membrane expression involves the Golgi complex.
17635496 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17622941 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17568401 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17568401 Suggest a potential association between the OATP1B1 genetic polymorphisms and altered rosuvastatin pharmacokinetics in Korean populations.
17496208 Bosentan uptake into Chinese hamster ovary cells expressing human OATP1B1 or OATP1B3, and was efficiently inhibited by cyclosporin A, rifampicin, and to a lesser extent by sildenafil.
17473846 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17460607 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17460607 Although the SLCO1B1 polymorphism was found to have a significant effect on the pharmacokinetics of pitavastatin, a nonsynonymous ABCG2 variant, 421C>A, did not appear to be associated with the altered pharmacokinetics of pitavastatin.
17439540 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17439540 The 521T-->C polymorphism of SLCO1B1 appears to modulate significantly the total cholesterol-lowering efficacy of pravastatin in Chinese patients with CHD.
17415554 Observational study of genotype prevalence. (HuGE Navigator)
17415554 We found eight polymorphic variants that differed in genotypic and allelic frequencies between the Chinese, Malay and Indian populations.
17412826 results indicate that OATP1B3/OATP-8 and OATP1B1/OATP-C most likely function as bidirectional facilitated diffusion transporters and that GSH is not a substrate or activator of their transport activity.
17108811 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
17108811 SLCO1B1 polymorphism markedly affects the pharmacokinetics of active simvastatin acid, but has no significant effect on parent simvastatin.
17047488 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16917677 Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16906022 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16847425 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16847425 SLCO1B1 polymorphism does not affect the extent of induction of hepatic CYP3A4 by rifampicin.
16796707 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16784736 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16758257 Observational study of genotype prevalence. (HuGE Navigator)
16758257 Sequence variations of SLCO1B1 occur at high frequencies in the Caucasian population.
16722833 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16678545 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16678544 Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16568260 SLCO1B1 haplotypes seem to play a role in basal cholesterol homeostasis.
16568260 Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16542205 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16534140 OATP1B1 play an important roles in CDCA uptake into the liver.
16515396 Observational study of genetic testing. (HuGE Navigator)
16515396 single nucleotide polymorphisms has been proposed to cause functional alternations in OATP1B1 with shown consequences for the pharmacokinetics of drugs that are OATP1B1 substrates
16513443 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16513443 Increased exposures of OATP1B1 substrates might be expected in individuals who have the poor transporter phenotype or are treated with an OATP1B1 inhibitor
16255851 Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
16198653 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16198652 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
16004557 Observational study of genetic testing. (HuGE Navigator)
15961978 Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)
15952872 Observational study of gene-disease association. (HuGE Navigator)
15864131 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
15864125 UGT1A1, OATP2 and G6PD genes have roles in genetic predisposition to unconjugated hyperbilirubinemia
15548849 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
15535988 Inhibition of OATP1B1 is an important mechanism for drug-induced unconjugated hyperbilirubinemia.
15519273 Observational study of gene-disease association. (HuGE Navigator)
15319464 neonates who carry the 211 and 388 variants in the UGT1A1 and OATP 2 genes, respectively, as well as feed with breast milk are at high risk to develop severe hyperbilirubinemia.
15226675 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
15226675 In heterozygous carriers the pharmacokinetics of pravastatin were higher compared to non-carriers.
15116054 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
12811365 Clinical trial of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)
12811365 commonly occurring single-nucleotide polymorphisms in OATP-C, such as T521C (Val174Ala), are likely to be associated with altered pharmacokinetics of pravastatin
12670950 a role for OATP2 in hepatocyte bilirubin transport is unlikely
12490595 human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
12196548 A naturally occurring mutation in the gene causes impaired membrane localization of the hepatocyte uptake transporter
12130747 Observational study of genotype prevalence. (HuGE Navigator)
12130747 Genetic polymorphisms: allele frequencies in the Japanese population and functional analysis
11483603 The promoter of SLC21A6 gene was characterized and regulated by HNF 1alpha.
11477075 Observational study of genotype prevalence. (HuGE Navigator)

AA Sequence

MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKSSIIHIERRFEISSSLVGFID      1 - 70
GSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCFIMGIGGVLTALPHFFMGYYRYSKETNINSSENSTSTLS     71 - 140
TCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNMLRGIGETPIVPLGLSYIDDFAKEGHSSLYLG    141 - 210
ILNAIAMIGPIIGFTLGSLFSKMYVDIGYVDLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLP    211 - 280
QTPNKPQKERKASLSLHVLETNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVS    281 - 350
SYIGAFTYVFKYVEQQYGQPSSKANILLGVITIPIFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLS    351 - 420
FYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGITYISPCLAGCK    421 - 490
SSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAIQVLNLFFSALGGTSHVMLIV    491 - 560
KIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCIKWSTNNCGTRGSCRTYNSTSFSRVYLGLSS    561 - 630
MLRVSSLVLYIILIYAMKKKYQEKDINASENGSVMDEANLESLNKNKHFVPSAGADSETHC             631 - 691
//

Text Mined References (261)

PMID Year Title
27455553 2016 Construction of HEK293 cells stably expressing wild-type organic anion transporting polypeptide 1B1 (OATP1B1*1a) and variant OATP1B1*1b and OATP1B1*15.
26607661 2015 SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.
26562723 2015 Amino Acid Residues in the Putative Transmembrane Domain 11 of Human Organic Anion Transporting Polypeptide 1B1 Dictate Transporter Substrate Binding, Stability, and Trafficking.
26482301 2015 Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
26474710 2015 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
26409184 2015 Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
26383540 2016 Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
26380303 2015 Systemic Inflammation in Duchenne Muscular Dystrophy: Association with Muscle Function and Nutritional Status.
26376374 2015 Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
26373210 2015 Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
26334733 2015 Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.
26334272 2015 SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
26191226 2015 Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.
26146841 2015 Multiple Genetic Modifiers of Bilirubin Metabolism Involvement in Significant Neonatal Hyperbilirubinemia in Patients of Chinese Descent.
26122863 2015 Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry.
26009271 2015 Protein kinase C affects the internalization and recycling of organic anion transporting polypeptide 1B1.
25992810 2015 SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
25935875 2015 Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
25916517 2015 SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.
25812934 2015 Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells.
25701109 2015 Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.
25578040 2015 Effects of anthocyans on the expression of organic anion transporting polypeptides (SLCOs/OATPs) in primary human hepatocytes.
25499601 2014 Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study.
25498879 2015 Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort.
25488931 2015 Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship.
25414411 2015 Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
25391605 2015 Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.
25379722 2015 Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort.
25130190 2014 Impact of SLCO1B1 521T?>?C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
25124723 2014 SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
25098908 2014 Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.
25084202 2014 Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments.
24989890 2014 Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
24865931 2014 Combined effects of the UGT1A1 and OATP2 gene polymorphisms as major risk factor for unconjugated hyperbilirubinemia in Indian neonates.
24855184 2014 Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
24825069 2015 Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.
24816252 2014 An atlas of genetic influences on human blood metabolites.
24810685 2014 Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
24762081 2014 SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
24740327 2014 Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3.
24673529 2014 Cysteine scanning mutagenesis of transmembrane domain 10 in organic anion transporting polypeptide 1B1.
24623479 2014 Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.
24595600 2014 Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
24420746 2014 Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
24324551 2013 Genome wide association study (GWAS) of Chagas cardiomyopathy in Trypanosoma cruzi seropositive subjects.
24275569 2014 An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
24263182 2014 The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
24194513 2014 Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
24090270 2013 Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China.
23970802 2013 SLCO1B1 variants and urine arsenic metabolites in the Strong Heart Family Study.
23942138 2013 SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink.
23930675 2013 Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
23929842 2013 Differential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with interleukin-6 production.
23886114 2014 In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
23858103 2013 Conserved tryptophan residues within putative transmembrane domain 6 affect transport function of organic anion transporting polypeptide 1B1.
23850112 The impact of SLCO1B1 genetic polymorphisms on neonatal hyperbilirubinemia: a systematic review with meta-analysis.
23778707 2013 International Transporter Consortium commentary on clinically important transporter polymorphisms.
23708174 2013 Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
23670789 2013 Effects of Rifampin, a potent inducer of drug-metabolizing enzymes and an inhibitor of OATP1B1/3 transport, on the single dose pharmacokinetics of anacetrapib.
23652803 2013 Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
23625433 2013 Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.
23556337 2013 CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
23503447 2013 Discordant associations between SLCO1B1 521T?C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
23471819 2013 Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method.
23461378 2013 Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA.
23436703 2013 Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example.
23361102 2013 Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
23340295 2013 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
23285087 2012 N-Glycosylation dictates proper processing of organic anion transporting polypeptide 1B1.
23281178 2013 A genome-wide assessment of variability in human serum metabolism.
23263738 2013 Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
23248200 2013 Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.
23243220 2013 Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.
23233662 2013 Genome-wide study of methotrexate clearance replicates SLCO1B1.
23216274 2013 Influence of the functional polymorphisms in the organic anion transporting polypeptide 1B1 in the susceptibility to colorectal cancer.
23190519 2012 Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
23010650 2012 Contribution of the OATP1B subfamily to cancer biology and treatment.
22842957 2013 Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
22829776 2012 A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation.
22771883 2012 Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.
22749334 2012 Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
22695893 2012 Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
22574206 2012 Identification of amino acids essential for estrone-3-sulfate transport within transmembrane domain 2 of organic anion transporting polypeptide 1B1.
22562052 2012 SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury.
22505549 2012 SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
22240838 2012 Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake.
22232210 2012 Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
22203093 2012 Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy.
22189199 2012 Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
22178260 2012 Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs.
22147369 2012 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
22136368 2012 Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.
22088425 2012 Association of SLCO1B1 1b with peptic ulcer amongst Japanese patients taking low-dose aspirin.
22041697 2011 [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
22016628 2011 Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
21992719 2011 SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.
21902813 2012 Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings.
21886157 2011 Human metabolic individuality in biomedical and pharmaceutical research.
21882531 2011 [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers].
21851379 2012 The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin.
21849517 2011 Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.
21787759 2011 OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture.
21743379 2011 CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
21719246 2011 Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport.
21709081 2011 The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
21691816 2011 OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation.
21655991 2011 No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
21646302 2011 Mayo Genome Consortia: a genotype-phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels.
21500146 2011 Neonatal hyperbilirubinemia and organic anion transporting polypeptide-2 gene mutations.
21457551 2011 The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.
21327909 2011 Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.
21309757 2011 Association of polymorphisms in the solute carrier organic anion transporter family member 1B1 gene with essential hypertension in the Uyghur population.
21245207 2011 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
21243006 2012 Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
21092521 2010 [OATP 1B1 T521C/A388G is an important polymorphism gene related to neonatal hyperbilirubinemia].
21072184 2010 Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
20973885 2011 Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India.
20877131 2010 Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.
20839930 2010 Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
20837016 2010 Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition.
20827719 2010 Liver X receptor ? and farnesoid X receptor are major transcriptional regulators of OATP1B1.
20712525 2010 Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.
20679960 2010 Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients.
20660695 2010 Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
20635135 2011 Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk.
20602615 2010 Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
20514852 2009 Variants of organic anion transporter polypeptide 2 gene are not risk factors associated with severe neonatal hyperbilirubinemia.
20406215 2010 SLCO1B1 polymorphism and oral antidiabetic drugs.
20403997 2010 Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
20389299 2010 Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.
20347093 2010 Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.
20212519 2011 Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
20207952 2010 Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
20175818 2010 OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers.
20173083 2010 Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.
20078617 2010 The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
20051929 2010 HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
20040338 2010 Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
20031551 2008 Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
19956635 2009 Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies.
19952871 2010 PharmGKB very important pharmacogene: SLCO1B1.
19934028 2010 Gender is an important determinant of the disposition of the loop diuretic torasemide.
19901119 2009 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
19890249 2010 The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.
19858149 2009 Complex multifactorial nature of significant hyperbilirubinemia in neonates.
19842932 2009 Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
19833260 2009 The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
19776292 2009 Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.
19771428 2010 Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
19760661 2009 Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1.
19667110 2009 Identification of genetic variants associated with response to statin therapy.
19642078 2010 Prevalence of risk factors for statin-induced myopathy in rheumatoid arthritis patients.
19620935 2009 Impact of regulatory polymorphisms in organic anion transporter genes in the human liver.
19590950 2010 The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer.
19442037 2009 Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
19414484 2009 Genome-wide association meta-analysis for total serum bilirubin levels.
19397531 2009 Genetic polymorphisms in Thai neonates with hyperbilirubinemia.
19390945 2009 UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
19387419 2009 Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
19374892 2009 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
19349540 2009 Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
19343046 2009 Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects.
19293444 2009 Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease.
19244099 2009 The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17beta-D-glucuronide.
19243019 2009 Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations.
19238654 2008 Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
19238167 2009 Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy.
19238116 2009 Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population.
19144951 2009 SLCO1B1 variants and statin-induced myopathy.
19129086 2008 Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.
19122343 2008 Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore.
19005461 2009 Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
18854776 2008 Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
18823304 2008 The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
18794729 2008 Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
18781850 2008 Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.
18695635 2008 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
18650507 2008 SLCO1B1 variants and statin-induced myopathy--a genomewide study.
18641915 2008 Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism.
18558634 2008 Coexpression of gene polymorphisms involved in bilirubin production and metabolism.
18551036 2008 Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
18518855 2008 A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine.
18499754 2008 Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism.
18443034 2008 Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin.
18408565 2008 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.
18399713 2008 Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
18321482 2008 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.
18314419 2008 Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
18221820 2009 Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
18192894 2008 Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
18187595 2008 Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
18185926 2008 Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations.
18180273 2008 Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
18159134 2007 Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.
18154446 2008 Global analysis of genetic variation in SLCO1B1.
17996736 2008 Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations.
17989996 2008 Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.
17973861 2007 OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
17932728 2007 Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers.
17923851 2008 Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.
17906856 2007 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
17885626 2007 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
17883959 2007 Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients.
17766002 2008 Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
17641954 2008 Membrane trafficking of the human organic anion-transporting polypeptide C (hOATPC).
17635496 2008 No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
17622941 2007 Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.
17568401 2008 Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
17496208 2007 Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
17473846 2007 Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
17460607 2007 SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
17439540 2007 SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.
17415554 2007 Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
17412826 2007 Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport.
17108811 2006 SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
17047488 2006 Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
16917677 2006 Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.
16906022 2006 Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
16847425 2006 Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
16796707 2006 Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
16784736 2006 Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
16758257 2006 Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
16722833 2006 Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
16678545 2006 Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
16678544 2006 Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
16568260 2006 Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels.
16542205 2006 Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
16534140 2006 Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3.
16515396 2006 Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.
16513443 2006 Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
16255851 2005 [Role of genetic factors in occurrence of neonatal jaundice in Guangxi region].
16198653 2005 Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
16198652 2005 Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
16004557 2005 Rapid genotyping of the OATP1B1 polymorphisms A388G and T521C with real-time PCR FRET assays.
15961978 2005 Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
15952872 2005 CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
15864131 2005 Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.
15864125 2005 Genetic factors related to unconjugated hyperbilirubinemia amongst adults.
15548849 2004 Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
15535988 2004 Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.
15519273 2004 Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects.
15489334 2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
15319464 2004 Risk factors for severe hyperbilirubinemia in neonates.
15226675 2004 High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
15116054 2004 Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
14702039 2004 Complete sequencing and characterization of 21,243 full-length human cDNAs.
14579113 2004 Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.
12811365 2003 Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
12670950 2003 The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport.
12490595 2003 Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
12477932 2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.
12196548 2002 A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter.
12130747 2002 Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.
11483603 2001 Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha.
11477075 2001 Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
11134001 2001 Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6.
10873595 2000 Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.
10779507 2000 Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide.
10644574 2000 A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane.
10601278 1999 A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.
10358072 1999 Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.